Navigation Links
Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
Date:9/17/2009

e prescription drugs used to treat a number of diseases and conditions, including those in the cardiovascular, metabolic, cancer, organ transplantation, central nervous system, dermatological, GI and respiratory areas. The company's mission is to improve people's lives by pioneering novel healthcare solutions.

Located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG, which provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, preventive vaccines, diagnostic tools, cost-saving generic pharmaceuticals, and consumer health products. Novartis is the only company with leading positions in these areas. In 2008, the Group's continuing operations achieved net sales of USD 41.5 billion and net income of USD 8.2 billion. Approximately USD 7.2 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 98,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.


'/>"/>
SOURCE Novartis Pharmaceuticals Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Video and Photo: EMD Serono Launches easypod(R), New Electronic Growth Hormone Injection Device
2. Video and Photo: Tekturna HCT(R), a Single-tablet Combination of Tekturna(R)* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure
3. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
4. Oral Drug From Novartis/Mitsubishi Tanabe Will Capture the Largest Market Share of All Emerging Multiple Sclerosis Therapies in 2017
5. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
6. Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe
7. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
8. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
9. Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US
10. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
11. Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... Limited (ASX:NRT; NASDAQ: NVGN ) ("Company" or "Novogen"), ... entered into definitive agreements today to issue approximately ... 6-month option and half of one attaching 5-year ... investors in the United States ... proceeds of approximately AU$15,500,000 ("Placement"). The closing of ...
(Date:4/21/2015)... April 21, 2015 Progyny, Inc., the ... LLC, announced that it has secured additional capital from ... Biotech, SR One and Merck Serono Ventures. The funding ... patients the best fertility outcomes by aligning science, technology, ... online marketplace for families seeking fertility solutions and we ...
(Date:4/21/2015)... 21, 2015 Whether it’s used for troubleshooting ... bolted to a Kessler CineDrive in a cinematic ... beach, the TS3-H is designed to help any shooter create ... state-of-the-art 5MP sensor, the TS5-H offers the same convenient touchscreen ... characteristics. , According to Tom Boldt for Fastec, “We ...
(Date:4/20/2015)... and MENLO PARK, Calif. ... Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the ... commercializing proven cancer therapies in new orphan drug ... 106th Annual Meeting of the American Association ... the potential for its lead product candidate ...
Breaking Biology Technology:Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 2Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 3Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 4Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 5Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 6Announcing Progyny: Combining Best-in-Class Clinical Solutions with Consumer Expertise 2Fastec Imaging Releases the TS5-H High Definition High-Speed Camera 2Fastec Imaging Releases the TS5-H High Definition High-Speed Camera 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 2DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 4DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 5
... processing revenues in the third, quarter of 2007 increased 25 percent ... ... Oct. 11 CryoLife, Inc. (NYSE: CRY ),a biomaterials, medical ... revenues for the third quarter,of 2007 were approximately $21.9 million compared ...
... Challenges and Opportunities to Realize ... Critical Path Initiative Goals, ... PHST), a leading provider of software,strategic consulting, and regulatory services ... senior vice,president and chief technology officer, has been invited to ...
... Solstice Neurosciences, Inc.,("Solstice") announced the appointment of ... Smith will serve as Executive Chairman replacing James,Thomas, ... Chairman since Solstice,was founded in July 2004. ... expertise to Solstice that will be invaluable in ...
Cached Biology Technology:CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million 2CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million 3CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million 4CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million 5Pharsight Invited to Present on Winning Strategies for R&D Productivity at New York Pharma Forum on October 15, 2007 2Pharsight Invited to Present on Winning Strategies for R&D Productivity at New York Pharma Forum on October 15, 2007 3Dennis L. Smith Appointed Executive Chairman to Board of Directors of Solstice Neurosciences, Inc. 2
(Date:3/20/2015)... and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) has announced the ... Report" report to their offering. This report ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... . Annual estimates and forecasts are provided ...
(Date:3/18/2015)... SPRINGS, Florida , March 18, 2015 ... well as businesses, new revolutionary smart wallets and apps continue ... pace.  Companies currently entrenched in the mobile payment industry in ... Alibaba Group Holding Ltd. (NYSE: BABA ), Apple ... GOOG ) and Facebook Inc. (NASDAQ: FB ...
(Date:3/17/2015)... , March 17, 2015 Emotient, ... analytics software, today announced general availability of ... service for the analysis of facial expressions. The ... advertising, media content, products and services. It delivers ... engagement and sentiment - as derived from facial ...
Breaking Biology News(10 mins):Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4
... your average persons idea of a good time, but for ... I think worms are totally cool, like humans only simpler ... working with the invertebrates is what will bring Dr. Fraser ... he will present some of his research findings in a ...
... ALBUQUERQUE, N.M. As Americans demand new and cleaner ... turning to algae as a promising new fuel source. ... nation,s reliance on imported oil while contributing to rural ... that algae-based biofuels could displace large volumes of diesel ...
... The American Association for Dental Research (AADR) has announced ... Chilton Fellowship in Clinical Research recipient. He will be ... Washington, DC, March 3, 2010. Currently, Dawson is ... the Delta Dental of Kentucky Clinical Research Center, in ...
Cached Biology News:The impact of genomics 2Fueling the future with fish tank residue: Sandia scientist discusses use of algae as a biofuel 2Fueling the future with fish tank residue: Sandia scientist discusses use of algae as a biofuel 3Fueling the future with fish tank residue: Sandia scientist discusses use of algae as a biofuel 4
Preparation TW--Compatibility: no end cap seals -Hybridization Tube for Hybrigene -Comp Dim: 240 80 mm -Material: borosilicate glass -Mfr Desig: Techne FHB-15...
...
... For use in hybridization incubators ... and GL 45 size PP plug-seal ... seal. Available in three lengths to ... plug-seal caps and O-rings available separately. ...
... gels The SpinPrep Gel DNA Kit enables efficient ... 12,000 bp in size from agarose gels. The procedure ... by adsorption of the DNA to a silica membrane ... the purified DNA is eluted in low-salt buffer. Each ...
Biology Products: